4 results
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
9 May 24
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:11pm
of top-tier investors. With a clean safety profile in SPY001's 28-day GLP toxicity study, we remain on track towards initiating a first-in-human
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
8 Sep 23
Material Modifications to Rights of Security Holders
5:05pm
adalimumab (Humira) in UC. Clean safety profile since approval in 2014. #1 biologic in IBD bio-naïve patients in the US.1 1. Takeda JPM 2023 presentation … maintenance remission Safety Clean safety profile / manageable AE profile expected for class Extremely clean safety profile
Assuming equivalent
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
23 Jun 23
Entry into a Material Definitive Agreement
9:16am
) in UC. Clean safety profile since approval in 2014. #1 biologic in IBD bio-naïve patients in the US.1 1. Takeda JPM 2023 presentation. Figure data
- Prev
- 1
- Next